Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine
Restricted accessResearch articleFirst published online August, 2015
Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine
Highly active antiretroviral therapy (HAART) contributed to the improvement in the life expectancy of HIV-infected patients. However, the emergence of drug-resistant mutations (DRM) is a major viral factor impacting therapeutic failure. Differences in DRM can occur among HIV-1 subtypes. We evaluate the kinetics of the selection of resistance mutations in vitro analyzing two chimeric clones that contain the reverse transcriptases of subtypes B or C (RTB′ and RTC′) in cells treated with increasing concentrations of tenofovir disoproxil fumarate (TDF) and didanosine (ddI). The mutation K65R is selected more quickly in RTC′ than in RTB′ viruses with TDF and ddI, and additional mutations (positions 45, 62, and 68) were selected after K65R fixation. Other primary mutations (M184V and Q151M) were selected with ddI treatment in conjunction with K65R only in RTC′ viruses. Both patterns, M184V+K65R and Q151M+K65R, have a significant impact on NRTI resistance. Our data suggest that selection of TDF and ddI DRMs can occur earlier in subtype C HIV in patients when compared to subtype B.
Get full access to this article
View all access options for this article.
References
1.
(UNAIDS), UJP on H: Global Report: UNAIDS Report on the Global AIDS Epidemic, 2013.
2.
WHO: Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2010.
3.
SteegenK, LevinL, KetseoglouI, et al.: High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One, 2014; 9:e97067.
4.
PetersRPH, Van RamshorstMS, StruthersHE, and McIntyreJA: Clinical assessment of peripheral neuropathy in HIV-infected children on antiretroviral therapy in rural South Africa. Eur J Pediatr, 2014; 173:1245–1248.
5.
LiuH, MaY, SuY, et al.: Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: A systematic review and meta-analysis. Clin Infect Dis, 2014; 59:1495–1502.
6.
LohseN, HansenA-BE, PedersenG, et al.: Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med, 2007; 146:87–95.
7.
HemelaarJ, GouwsE, GhysPD, and OsmanovS: Global trends in molecular epidemiology of HIV-1 during 2000–2007. AIDS, 2011; 25:679–689.
8.
SantosAF and SoaresMa: HIV Genetic diversity and drug resistance. Viruses, 2010; 2:503–531.
9.
LoembaH, BrennerB, ParniakMA, et al.: Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother, 2002; 46:2087–2094.
10.
BrennerB, TurnerD, OliveiraM, et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS, 2003; 17:F1–F5.
11.
CunhaRD, AbreuCM, GonzalezLMF, et al.: Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C. PLoS One, 2012; 7:e46622.
12.
RheeS-Y, LiuT, RavelaJ, et al.: Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing. Antimicrob Agents Chemother, 2004; 48:3122–3126.
13.
Doualla-BellF, AvalosA, BrennerB, et al.: High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother, 2006; 50:4182–4185.
14.
BrennerBG, OliveiraM, Doualla-BellF, et al.: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS, 2006; 20:F9–F13.
15.
MillerMD, MargotN, McCollD, and ChengAK: K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials. AIDS, 2007; 21:265–266.
16.
Von WylV, EhteshamiM, SymonsJ, et al.: Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis, 2010; 201:1054–1062.
17.
Van MaarseveenNM, HuigenMCDG, de JongD, et al.: A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J Virol Methods, 2006; 133:185–194.
18.
IordanskiyS, WaltkeM, FengY, and WoodC: Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. Retrovirology, 2010; 7:1–18.
19.
WensingAM, CalvezV, GünthardHF, et al.: 2014 update of the drug resistance mutations in HIV-1. Top Antivir Med, 2014; 22:642–650.
20.
SunpathH, WuB, GordonM, et al.: High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen. AIDS, 2012; 26:1679–1684.
21.
KarimQ, KarimS, FrohlichJ, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329:1168–1174.
22.
ThigpenMC, KebaabetswePM, PaxtonLA, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med, 2012; 367: 423–434.
23.
BaetenJM, DonnellD, NdaseP, et al.: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med, 2012; 367:399–410.
24.
MargotNA, WatersJM, and MillerMD: In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother, 2006; 50:4087–4095.
25.
StoneC, Ait-khaledM, CraigC, et al.: Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine. Antimicrob Agents Chemother, 2004; 48:1413–1415.
26.
Van RompayKKA, JohnsonJA, BlackwoodEJ, et al.: Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology, 2007; 4:1–22.
27.
RossLL, RouseE, GerondelisP, et al.: Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir. J Antimicrob Chemother, 2010; 65:307–315.
28.
LaflammeG, GrantD, WhiteK, et al.: Novel nucleotide inhibitor GS-9148 selects for a K70E mutation in HIV-1 reverse transcriptase and low-level resistance in vitro. Poster Section. Presented at the 47th Interscience Conference Antimicrob Agents Chemother 2007, September. Chicago, IL.
29.
RheeS-Y, GonzalesMJ, KantorR, et al.: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res, 2003; 31:298–303.
30.
CoutsinosD, InvernizziCF, XuH, et al.: Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol, 2009; 83:2029–2033.
31.
InvernizziCF, CoutsinosD, OliveiraM, et al.: Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis, 2009; 200:1202–1206.
32.
MolinaJ, MarcelinA-G, PavieJ, et al.: Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J Infect Dis, 2005; 191:840–847.
33.
GuZ, GaoQ, LiX, et al.: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2', 3'- dideoxyinosine and 2', 3'- dideoxycytidine. J Virol, 1992; 66:7128–7135.
34.
GaoQ, GuZ, ParniakMA, et al.: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′, 3′-dideoxyinosine and 2′, 3′-dideoxycytidine confers high-level resistance to the ( - ) enantiomer of 2′, 3′ -dideoxy-3′-thiacytidine. Antimicrob Agents Chemother, 1993; 37:1390–1392.
35.
ShaferRW, KozalMJ, WintersMA, et al.: Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis, 1994; 169:722–729.
36.
Waléria-AleixoA, MartinsAN, ArrudaMB, et al.: Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns. Antimicrob Agents Chemother, 2008; 52:4497–4502.
37.
KumarasamyN, MadhavanV, VenkateshKK, et al.: High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: Implications for second-line options in resource-limited settings. Clin Infect Dis, 2009; 49:306–309.
38.
NouhinJ, MadecY, Ngo-Giang-HuongN, et al.: Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia. PLoS One, 2013; 8:1–4.
39.
DevalJ, NavarroJ-M, SelmiB, et al.: A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem, 2004; 279:25489–25496.
40.
SharmaPL, NurpeisovV, LeeK, et al.: Replication-dependent 65R– >K reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R+L74V. Virology, 2004; 321:222–234.
41.
RathBa, YousefKP, KatzensteinDK, et al.: In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors and in silico phenotypic analysis. PLoS One, 2013; 8:1–12.
